
- /
- Supported exchanges
- / TO
- / GUD.TO
Knight Therapeutics Inc. (GUD TO) stock market data APIs
Knight Therapeutics Inc. Financial Data Overview
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Knight Therapeutics Inc. data using free add-ons & libraries
Get Knight Therapeutics Inc. Fundamental Data
Knight Therapeutics Inc. Fundamental data includes:
- Net Revenue: 385 M
- EBITDA: 37 569 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: 0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Knight Therapeutics Inc. News

Mawer New Canada Fund Exits Softchoice Corp, Impacting Portfolio by -3.14%
This article first appeared on GuruFocus. Insightful Moves in the Second Quarter of 2025 Mawer New Canada Fund (Trades, Portfolio) recently submitted its report for the second quarter of 2025, shedd...


Knight Announces Normal Course Issuer Bid
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the...

Knight Therapeutics Q2 Net Loss Widens, Revenue Rises
Knight Therapeutics (GUD.TO), up 1.6% in early trade, on Thursday said second-quarter net loss widen PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

Knight Therapeutics Reports Second Quarter 2025 Results
Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Compan...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.